Business Wire

NTT Launches IoT Services for Sustainability

2.5.2022 11:00:00 EEST | Business Wire | Press release

Share

NTT Ltd., a global technology and business solutions provider, today announced the launch of its IoT Services for Sustainability offering. The new end-to-end stack of solutions will help businesses advance progress against global sustainability initiatives and make data-driven decisions to reduce their carbon footprint through the intelligent use of IoT connectivity.

These solutions include:

  • OCR Meter Reading: An optical-based meter reader to provide near real-time data from any type of meter including water, electricity, and gas. The meter can also be used to read any type of gauge including pressure and temperature.
  • Water Leak Management: This technology provides real-time, IoT enabled protection against water damage for smart spaces projects.
  • Predictive Maintenance: This solution collects data from sensors to create models that predict when events of interest might occur, including potential downtime, accidents or when something might need to be replaced.
  • Environmental Monitoring: This technology uses sensors to identify the presence of pollutants in the air and water as well as tracking temperature and humidity.

NTT’s IoT Services for Sustainability stack incorporates a secure IT/OT integration and end-to-end support. This helps organizations to quickly see the benefits of the technology across the entire business following deployment. Benefits include energy cost savings, faster reduction in emissions, advanced operational excellence, and better work enablement across the organization. The stack of solutions is also supported by NTT’s new LoRaWAN network, and its catalog of sensors to measure, monitor and collect data to drive sustainability objectives.

“IoT technologies are an essential tool in the global fight against climate change,” said Jeff Merritt, Head of Urban Transformation at the World Economic Forum. “We know what actions are needed to build a more sustainable future and have a robust suite of technologies available to help deliver this impact. As the world looks to accelerate the implementation of these solutions, organizations like NTT will have a critical role to play in helping companies and governments capitalize on this opportunity.”

This announcement follows the appointment of two industry veterans to drive growth and momentum across NTT’s IoT and sustainability initiatives. Wireless industry leader Devin Yaung has been appointed as SVP of Group Enterprise IoT Products and Services, NTT Ltd., bringing over 25 years of technology experience focused on business transformation. Vicky Bullivant has also been appointed as Senior Vice President, Group Sustainability, NTT Ltd. Vicky has 25 years of creating and delivering successful sustainability, social, climate and ESG strategies that underpin commercial objectives in fast-paced and evolving business environments.

"Almost two-thirds (61.4%) of CEOs say they’re aligning business strategies to the UN’s Sustainable Development Goals. Yet only 2 out of 5 businesses have the solutions needed to meet the organization's immediate objectives,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services.

"Therefore, it is more critical than ever to prioritize and deliver sustainability solutions for our enterprise customers. Our new stack of solutions will help organizations reach their sustainability goals and improve operations across their business, whether it is reducing waste from manufacturing defects or understanding the carbon footprint of their supply chain. The use of IoT will empower businesses to make decisions in real-time, streamlining processes and transforming the overall sustainability of their business. We’re proud to be announcing this offering at such a critical time, and we look forward to driving change alongside our clients to create a more sustainable future."

To find out more about NTT’s IoT Services for Sustainability solutions, please visit here.

About NTT Ltd.
NTT Ltd. is a leading, global technology services company. To help our clients achieve their digital transformation goals, we use our global capabilities, expertise, and full-stack technology services delivered through our integrated services platform. As their long-term strategic partner, we help them enhance customer and employee experience, transform their cloud strategy, modernize their networks and strengthen their cybersecurity. And across their transformation priorities, we automate their business processes and IT, drawing insights and analytics from their core business data. As a global ICT provider, we employ more than 50,000 people across 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.

Visit us at services.global.ntt

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Hotwire for NTT Ltd.
Hannah Lock
NTT@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye